Compass Pathways Plc (CMPS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Compass Pathways Plc (CMPS) has a cash flow conversion efficiency ratio of 0.715x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-37.79 Million) by net assets ($-52.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Compass Pathways Plc (CMPS) balance sheet quality index to measure how much of total assets are equity-financed.
Compass Pathways Plc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Compass Pathways Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how much of Compass Pathways Plc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Compass Pathways Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Compass Pathways Plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Datang Telecom Technology Co Ltd
SHG:600198
|
0.015x |
|
TianJin 712 Communication & Broadcasting Co Ltd
SHG:603712
|
-0.055x |
|
Derichebourg
PA:DBG
|
0.205x |
|
FMC Corporation
NYSE:FMC
|
0.303x |
|
Leggett & Platt Incorporated
NYSE:LEG
|
-0.054x |
|
Jiangsu Yunyi Electric
SHE:300304
|
0.032x |
|
IMDEX Ltd
AU:IMD
|
0.085x |
|
BigBearai Holdings Inc
NYSE:BBAI
|
-0.023x |
Annual Cash Flow Conversion Efficiency for Compass Pathways Plc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Compass Pathways Plc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Compass Pathways Plc (CMPS) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-52.85 Million | $-157.24 Million | 2.975x | +486.18% |
| 2024-12-31 | $154.69 Million | $-119.19 Million | -0.770x | -78.61% |
| 2023-12-31 | $225.74 Million | $-97.38 Million | -0.431x | +25.85% |
| 2022-12-31 | $181.28 Million | $-105.45 Million | -0.582x | -144.21% |
| 2021-12-31 | $284.41 Million | $-67.75 Million | -0.238x | -13.15% |
| 2020-12-31 | $196.56 Million | $-41.38 Million | -0.211x | +89.93% |
| 2019-12-31 | $8.52 Million | $-17.81 Million | -2.091x | -406.57% |
| 2018-12-31 | $-14.37 Million | $-9.80 Million | 0.682x | -- |
About Compass Pathways Plc
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly … Read more